Jennifer Grodberg, Ph.D., RAC
Senior VP, Regulatory Affairs and Program Management
Jennifer Grodberg, PhD, RAC has over 24 years of experience in the pharmaceutical industry, spanning the pre-IND enabling phase through NDA submission, including FDA pre-approval inspections and Advisory Committee Meetings. Prior to joining Forge, Jenny was VP, Regulatory Affairs at VenatoRx Pharmaceuticals, leading the successful IND filing and acquisition of both Qualified Infectious Disease Product and Fast Track designations for their lead β-lactam/ β-lactamase antibiotic program VNRX-5133. She previously served as Senior Director of Regulatory Affairs at Trius Therapeutics, Inc., participating in the development and ultimate FDA approval of the oxazolidinone antibiotic Sivextro. Before entering the pharmaceutical industry, Jenny held a faculty appointment at Harvard Medical School in the Department of Medicine. Jenny has a PhD in Microbiology and completed postdoctoral work at both the Weizmann Institute of Science in Rehovot, Israel, and Harvard Medical School. For fun, Jenny enjoys the theatre and dance performances, plus is an avid binge reader.